Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus - Trial NCT05272059
Access comprehensive clinical trial information for NCT05272059 through Pure Global AI's free database. This Phase 1 trial is sponsored by Novartis Pharmaceuticals and is currently Not yet recruiting. The study focuses on Type 1 Diabetes Mellitus. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
Phase 1
Feb 13, 2023
Apr 14, 2025
Primary Outcome
Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)
Summary
The purpose of this two-part multiple ascending dose study is to evaluate the safety and
 tolerability of multiple doses of MHS552 in adults with type 1 diabetes mellitus.
 Participants will be treated for 4 or 12 weeks followed by an 8 week follow-up period
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05272059
Non-Device Trial